The Systematic Rate Research of Ezetimibe Combination with Simvastatin on Blood Lipids in Patients with Acute Coronary Syndrome

Objective To research the systematic rate of ezetimibe combined with simvastatin on blood lipids in patients with acute coronary syndrome(ACS).Methods All the ACS patients were diagnosis first,80 cases were randomly divided into two groups,one group given simvastatin(40mg/d),another group given simvastatin(40mg/d) and ezetimibe(10mg/d) combination,blood lipids compliance rate and adverse reactions incidencewere compared after 6 weeks.Results Compared with before the treatment,the two groups in total cholesterol,LDL,triglyceride levels were significantly reduced;compared with before the treatment of HDL-C level of the joint group increased,but no significant difference;LDL-compliance rates of the lipid was higher than simvastatin group.The incidence of adverse reactions of the combined group was no significant differencecompared with the simvastatin group.Conclusion ezetimibe combined with simvastatin can increase the compliance rate of serum lipids in patients with ACS,better than simvastatin,and security;ezetimibecombined with simvastatin can be applied to the initial lipid-lowering therapy in ACS.